Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Role of the pharmacist in preventing distribution of counterfeit medications.

Chambliss WG, Carroll WA, Kennedy D, Levine D, Moné MA, Ried LD, Shepherd M, Yelvigi M.

J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):195-9. doi: 10.1331/JAPhA.2012.11085. Review.

PMID:
22370383
2.

Roles for pharmacy in combatting counterfeit drugs.

Ziance RJ.

J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):e71-88; quiz e89-91. doi: 10.1331/JAPhA.2008.07069. Review.

PMID:
18653407
3.

Combating counterfeit medications: the California pharmacist perspective.

Law E, Youmans SL.

J Pharm Pract. 2011 Feb;24(1):114-21. doi: 10.1177/0897190010380745. Epub 2010 Oct 15.

PMID:
21507880
4.

Assessing the problem of counterfeit medications in the United Kingdom.

Jackson G, Patel S, Khan S.

Int J Clin Pract. 2012 Mar;66(3):241-50. doi: 10.1111/j.1742-1241.2011.02826.x. Epub 2011 Nov 9. Review.

PMID:
22070229
5.

Integration of temperature-controlled requirements into pharmacy practice.

Ziance R, Chandler C, Bishara RH.

J Am Pharm Assoc (2003). 2009 May-Jun;49(3):e61-7; quiz e68-9. doi: 10.1331/JAPhA.2009.08140. Review.

PMID:
19443313
6.

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.

Jackson G, Arver S, Banks I, Stecher VJ.

Int J Clin Pract. 2010 Mar;64(4):497-504. doi: 10.1111/j.1742-1241.2009.02328.x. Epub 2010 Jan 18. Review.

7.

Pharmaceutical counseling: Between evidence-based medicine and profits.

Egorova SN, Akhmetova T.

Int J Risk Saf Med. 2015;27 Suppl 1:S87-8. doi: 10.3233/JRS-150701.

PMID:
26639727
9.

[Counterfeit medicines--Japan and the world].

Sato D.

Yakugaku Zasshi. 2014;134(2):213-22. Review. Japanese.

10.
11.
13.

Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States.

Qureshi ZP, Norris L, Sartor O, McKoy JM, Armstrong J, Raisch DW, Garg V, Stafkey-Mailey D, Bennett CL.

J Oncol Pract. 2012 Mar;8(2):84-90. doi: 10.1200/JOP.2011.000325. Epub 2011 Dec 13.

14.

Integrating pharmacogenomics into pharmacy practice via medication therapy management.

Reiss SM; American Pharmacists Association..

J Am Pharm Assoc (2003). 2011 Nov-Dec;51(6):e64-74. doi: 10.1331/JAPhA.2011.11543.

PMID:
22001957
15.

[Counterfeit drugs as a gobal threat to health].

Golocorbin Kon S, Mikov M.

Med Pregl. 2011 May-Jun;64(5-6):285-90. Review. Serbian.

PMID:
21789919
16.

Counterfeit medications and their negative impacts on health care.

Fincham JE.

Am J Pharm Educ. 2014 Apr 17;78(3):48. doi: 10.5688/ajpe78348. No abstract available.

17.

Legislations combating counterfeit drugs in Hong Kong.

Lai CW, Chan WK.

Hong Kong Med J. 2013 Aug;19(4):286-93.

18.

Specialty pharmacies and other restricted drug distribution systems: financial and safety considerations for patients and health-system pharmacists.

Kirschenbaum BE.

Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S13-20. doi: 10.2146/ajhp090462.

PMID:
19966075
19.

[Anti-counterfeit activities of pharmaceutical companies in Japan: for patient safety].

Shofuda K, Aragane K, Igari Y, Matsumoto K, Ito K.

Yakugaku Zasshi. 2014;134(2):203-11. Review. Japanese.

20.

Counterfeit drug demand: perceptions of policy makers and community pharmacists in Sudan.

Alfadl AA, Hassali MA, Ibrahim MI.

Res Social Adm Pharm. 2013 May-Jun;9(3):302-10. doi: 10.1016/j.sapharm.2012.05.002. Epub 2012 Jul 25.

PMID:
22835708

Supplemental Content

Support Center